Framingham Heart Study to Use NuGen Amplification, Sample Prep Products | GenomeWeb

The National Heart, Lung, and Blood Institute has tapped NuGen Technologies to provide automated reagent solutions for expression profiling of approximately 6,000 blood samples from the landmark Framingham Heart Study, NuGen said this week.

NuGen's products will be used for an initiative that the Framingham Heart Study launched last year called the Systems Approach to Biomarker Research in Cardiovascular Disease, or SABRe CVD.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: mutations linked to nasopharyngeal carcinoma, salivary proteins common among oral squamous cell carcinoma patients, and more.

At Wired, a science journalist discusses her decision not to undergo BRCA testing.

The Japan Times says regulations are needed to oversee human genome-editing research.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.